Mib-626

Dementia

Brigham and Women's HospitalPhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 81/ 100

Competitive context

43 Active assets in the Dementia cohort.

Asset / Sponsor	Phase	Rating
Risperdal Hannover Medical School	Phase 4	BBB
CITALOPRAM Hannover Medical School	Phase 4	BBB
Galantamine Hydrobromide Janssen Pharmaceutica N.V., Belgium	Phase 3	BB
Namenda Zealand University Hospital	Phase 4	BB
Cipralex Ohio State University	Phase 4	BB

View all 50 →

Same molecule, other indications

Mib-626 is also rated in:

Friedreich ataxiaDormant

B

Indicative ·

57 / 100

Down syndromeDormant

CC

Indicative ·

43 / 100

Alzheimer diseaseDormant

NR

Indicative ·

/ 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.